Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
34.14 +0.98 (+2.96%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 34.14 unch (unch) 16:01 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
32.41
Day High
34.50
Open 33.17
Previous Close 33.16 33.16
Volume 1,103,500 1,103,500
Avg Vol 905,130 905,130
Stochastic %K 41.36% 41.36%
Weighted Alpha -34.45 -34.45
5-Day Change +1.71 (+5.27%) +1.71 (+5.27%)
52-Week Range 29.59 - 60.37 29.59 - 60.37
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,205,507
  • Shares Outstanding, K 93,893
  • Annual Sales, $ 560,230 K
  • Annual Income, $ -569,180 K
  • EBIT $ -536 M
  • EBITDA $ -513 M
  • 60-Month Beta 0.61
  • Price/Sales 5.56
  • Price/Cash Flow N/A
  • Price/Book 11.99

Options Overview Details

View History
  • Implied Volatility 83.38% ( +1.16%)
  • Historical Volatility 53.82%
  • IV Percentile 98%
  • IV Rank 63.95%
  • IV High 110.63% on 04/12/24
  • IV Low 35.02% on 06/25/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 8
  • Volume Avg (30-Day) 312
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 26,382
  • Open Int (30-Day) 24,183

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.58
  • Number of Estimates 8
  • High Estimate -1.06
  • Low Estimate -2.14
  • Prior Year -2.03
  • Growth Rate Est. (year over year) +22.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.59 +15.38%
on 04/09/25
Period Open: 38.33
40.53 -15.78%
on 03/13/25
-4.19 (-10.93%)
since 03/11/25
3-Month
29.59 +15.38%
on 04/09/25
Period Open: 42.07
46.50 -26.58%
on 02/06/25
-7.93 (-18.85%)
since 01/10/25
52-Week
29.59 +15.38%
on 04/09/25
Period Open: 50.70
60.37 -43.45%
on 09/16/24
-16.56 (-32.66%)
since 04/11/24

Most Recent Stories

More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 34.14 (+2.96%)
Ultragenyx to Participate at Investor Conferences in March

RARE : 34.14 (+2.96%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 34.14 (+2.96%)
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

RARE : 34.14 (+2.96%)
Ultragenyx: Q4 Earnings Snapshot

Ultragenyx: Q4 Earnings Snapshot

RARE : 34.14 (+2.96%)
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

RARE : 34.14 (+2.96%)
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

RARE : 34.14 (+2.96%)
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained...

RARE : 34.14 (+2.96%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 34.14 (+2.96%)
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

RARE : 34.14 (+2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 37.05
2nd Resistance Point 35.77
1st Resistance Point 34.96
Last Price 34.14
1st Support Level 32.87
2nd Support Level 31.59
3rd Support Level 30.78

See More

52-Week High 60.37
Fibonacci 61.8% 48.61
Fibonacci 50% 44.98
Fibonacci 38.2% 41.35
Last Price 34.14
52-Week Low 29.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar